Effect of Negative Pressure Wound Therapy After Surgical Removal of Deep-Seated High-Malignant Soft Tissue Sarcomas of the Extremities and Trunk Wall.
NCT ID: NCT04960332
Last Updated: 2022-07-06
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
NA
Total Enrollment
160 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-07-01
Study Completion Date
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The purpose of this research project is to improve the surgical treatment of Soft Tissue Sarcoma (STS) treatment based upon a Randomized Controlled Trial (RCT). We want to evaluate the effect of the use of Negative Pressure Wound Therapy (NPWT) versus a conventional wound dressing on postoperative wound complications after surgical removal of deep-seated high-malignant STS of the extremities or trunk wall.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
INPWT on Wound Complications & Clinical Outcomes After Lower Extremity Sarcoma Surgery Preop Radiation Therapy Patients
NCT03175718
Soft-tissue Sarcoma
Wound Complication
RECRUITING
NA
Randomised Control Study to Asses the Role of Negative Pressure Wound Therapy (NPWT) in the Management of Wound in Surgical Patient
NCT02331485
Wound Infection
Wound Complication
UNKNOWN
NA
The Effect of Negative Pressure Wound Therapy on Wound Healing in Major Amputations of the Lower Limb
NCT04618406
Negative-Pressure Wound Therapy
Amputation
Wound Heal
ACTIVE_NOT_RECRUITING
NA
Efficacy of Prophylactic Negative Pressure Wound Therapy (NPWT)
NCT05727995
Wound of Skin
UNKNOWN
NA
A Prospective, Open, Non-controlled Clinical Investigation to Evaluate a New Negative Pressure Wound Therapy (NPWT) System to be Used in the Treatment of Acute Non-infected Wounds and Post Surgical Infected Wounds
NCT01195896
Acute Non Infected Wounds
Non Infected Post Surgical Wounds
COMPLETED
NA
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Introduction
Sarcomas are a heterogeneous group of rare malignant tumors of mesenchymal cell origin in the musculoskeletal system comprising 1% of all adult cancers. The reported incidence of all types of sarcomas is approximately six to eight per 100,000 inhabitants corresponding to 300 cases per year in Denmark (250 STS (100 retroperitoneal/abdominal STS), 50 bone sarcomas). Sarcomas arise in the body's connective tissues including bone, muscle, cartilage, fat tissue, blood vessels, and peripheral nerve-sheaths and hence arise in all parts of the body although most dominant in the extremities (78%).
There exist more than 50 histologic subtypes of STS yielding a broad heterogeneous morphology and biological behavior of all subtypes. The incidence of STS is in general increasing with age (median age=65). High-grade soft tissue sarcomas mostly metastasize hematogenous to the lungs, which is also the primary cause of sarcoma-specific death and approximately 10% of patients with STS have metastases at diagnosis.
Treatment of STS requires a multidisciplinary highly specialized team, evaluating risks and benefits of all available options and expected outcomes with the aim to minimize the recurrence of disease and preserve function and quality of life. The main treatment principles that have largely been unchanged since the 1980ies is surgery supplemented with adjuvant radiotherapy depending on subtype and stage. The use of NPWT after high-risk orthopedic surgeries such as e.g. amputations, treatment of open fractures and joint replacement surgery are increasing, but the direct cost is much higher compared to the conventional wound dressing. However, previous studies have shown that NPWT can reduce postoperative complications such as wound dehiscence and infection. STS surgery that is often combined with pre-or postoperative radiation therapy is a high-risk procedure concerning wound complications and postoperative infections. A retrospective study showed that NPWT reduced the risk of wound complications in patients with lower extremity STS treated with preoperative radiation and the use of NPWT was not associated with an increased risk of local recurrence.
Methods
Study design
RCT (no blinding) where the patients will be randomized to wound closure with staples and either NPWT (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
Randomization
All 160 patients will in the operating room be randomized (randomization with 80 in each group) to receive one of the two treatment:
Group A: Standard wound closure with staples and conventional wound dressing. Group B: Wound closure with staples and NPWT (PREVENA PLUS™ Incision Management System).
Block randomization with 8 patients in each block stratified for upper extremity/truncal wall or lower extremity STS verified using a computerized irreversible application - the Research Electronic Data Capture (REDCap). The randomization sequence will be computer-generated.
Institutions
\- Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen and Department of Orthopedic Surgery, Aarhus University Hospital: The surgeries will be performed in these two department, both are tertiary multidisciplinary center performing highly specialized tumor surgeries.
Materials
Patients
Identification and inclusion Patients evaluated at a multidisciplinary conference and afterward with a biopsy verified STS will be identified in Sundhedsplatformen (electronic patient journal), the only information needed from the patient journal prior informed consent is when they will meet in the outpatient clinic. Patients eligible for inclusion will at their first outpatient visit to plan further final surgery be informed about the study written and orally. On the day of their surgery written informed consent will be obtained if they want to participate in this study. No patient will have below 48 hours to answer, complied with the Helsinki declaration.
All patients will be informed orally and written by the principal investigator, information will be given in a separate room allocated for only the patient and if wanted the assessor, so interruption occurs. All patient will be asked if they want an assessor and so a new meeting will be allocated and the information will again in a separate room allocated for the patient and the assessor be given by the principal investigator.
The written informed consent gives the principal investigator, sponsor and sponsor's representatives as well as any control authority direct access to obtain information in the patient's medical record, etc., including electronic medical record, in order to see information about the subject's health, which is necessary in carrying out the research project and for control purposes, including self-monitoring, quality control and monitoring, which they are required to perform.
The participants are covered by the Danish Patient Compensation Association.
Research plan
1. Clinical wound follow-up (n=160): preoperatively, 7 days, time for removal of staples and 4 months after surgery. To all examinations, clinical photos of the wound will be taken and stored in Sundhedsplatformen (electronic patient journal).
2. Clinical function evaluation (n=160): Musculoskeletal Tumor Society Score (MSTS) and Toronto Extremity Salvage Score (TESS) 4 months and 1 year postoperatively.
Follow-up
Patient's wounds will be followed with photo documentation on day 0, day 7, at definitive wound healing (removal of staples), 4 months postoperatively and in case of major wound complication by a member of the department staff or research group.
Follow-up from day 7 and further on will be performed in the outpatient regime, at Rigshospitalet, orthopedic department or the ortopedic department at Aarhus University Hospital, patients will be convened through e-boks and if necessary, transport will be provided.
Calculation of sample size
In the study of O'Sullivan et al. a major wound complication within 4 months postoperatively was identified in 16 out of 94 (17%) in the group of STS patients treated with surgery and postoperative radiation therapy. There exist no studies evaluating the effect of NPWT on wound complications after surgery for STS combined with postoperative radiation therapy. However, in retrospective studies it was found that NPWT reduced the risk of wound complications from 47% to 8% (83% reduction) in patients with lower extremity STS treated with preoperative radiation \[14\] and from 27% to 7% (75% reduction) in patients undergoing hip and knee revision surgery.
In a study design with an 80% risk of avoiding type II error, a 5% risk of type I error and an 80% wound complication risk reduction in a population similar to the study by O'Sullivan et al. the investigators will need to include 154 STS patients (77 in each group) in an RCT.
To make allowance for dropouts (since the follow-up period regarding the primary study endpoint is only 4 months = 120 days few dropouts are expected) during the study period the investigators plan to include 160 patients.
Risks, side effects and disadvantages
The investigators do not expect that the patients participating in the study will experience any special side effects or complications related directly to the specific use of NPWT or the standard wound closure. The dressing may for some patients give a mild skin irritation of the skin under the enclosed dressing or a slight discomfort with having to wear an occlusive dressing. Any skin irritation that is transient (i.e., resolves within 24 hours following device use and requires no medical intervention), will not be classified as an adverse device effect. Some blistering formations have been reported in relation to total hip and knee replacement surgery, but no more than tape trauma in patients with conventional dressing.
A retrospective study showed that NPWT reduced the risk of wound complications in patients with lower extremity STS treated with preoperative radiation and the use of NPWT was not associated with an increased risk of local recurrence.
No risk or side effects are reported by the manufacture when adhering to the manual of use.
Prevena™ NPWT are used daily at the orthopedic department, it is a CE classified medical devised and due to use in the recommended field approval from danish medicines agency are not necessary.
Ethical considerations
Approval from the Scientific Ethical Committee (H-21013549) and the Data Protection Agency (P-2021-150) has been obtained and the study is registered at clinicaltrial.gov NCT04960332. All patients will receive both oral and written information before written informed consent to participate is obtained.
The regulation from data protection regulation and data protection act will always be followed and a permission from data protection agency have been obtained (P-2021-150).
The significant use of the present study is new knowledge concerning the best way to treat a certain group of patients with deep-seated STS of an extremity or the trunk wall. Knowledge from our study will benefit society in general, and optimize utilization of resources, in terms of the best treatment for future patients.
In case of serious adverse preliminary results, data will be analyzed and if one of the treatments is found to cause significant critical problems compared to the other (p\<0.05), the study will be ended. The study is thus designed to minimize unnecessary risks to the patients.
Statistical analysis
Fisher's exact test will be used for categorical variables. Depending on if the data could be considered normally distributed or not, a t-test for unpaired data or Mann-Whitney U test will be used for continuous variables.
Kaplan Meier survival analysis for overall survival (with log-rank test for comparison of groups). In case of an assumption of a difference in time to delayed wound healing, competing risk analysis will be used to address differences between the groups with death and amputation as competing factors.
All analyses will be performed in accordance with the intention-to-treat principles.
Two-sided p-values below 0.05 will be considered statistically significant.
Time frame
According to the latest report from the Danish Sarcoma Registry, there were approximately 900 newly diagnosed sarcomas in Eastern Denmark (Rigshospitalet) during the 5 years from 2014 to 2018. The majority, but not all of the patients are suffering from high-malignant deep-seated STS of the extremities or the trunk wall. The inclusion of patients in the study will start at the first half of of 2021 thus leaving at least 3 years for inclusion and reserve 6 months for the PhD-student to do data management and writing.
Sarcomas are a heterogeneous group of rare malignant tumors of mesenchymal cell origin in the musculoskeletal system comprising 1% of all adult cancers. The reported incidence of all types of sarcomas is approximately six to eight per 100,000 inhabitants corresponding to 300 cases per year in Denmark (250 STS (100 retroperitoneal/abdominal STS), 50 bone sarcomas). Sarcomas arise in the body's connective tissues including bone, muscle, cartilage, fat tissue, blood vessels, and peripheral nerve-sheaths and hence arise in all parts of the body although most dominant in the extremities (78%).
There exist more than 50 histologic subtypes of STS yielding a broad heterogeneous morphology and biological behavior of all subtypes. The incidence of STS is in general increasing with age (median age=65). High-grade soft tissue sarcomas mostly metastasize hematogenous to the lungs, which is also the primary cause of sarcoma-specific death and approximately 10% of patients with STS have metastases at diagnosis.
Treatment of STS requires a multidisciplinary highly specialized team, evaluating risks and benefits of all available options and expected outcomes with the aim to minimize the recurrence of disease and preserve function and quality of life. The main treatment principles that have largely been unchanged since the 1980ies is surgery supplemented with adjuvant radiotherapy depending on subtype and stage. The use of NPWT after high-risk orthopedic surgeries such as e.g. amputations, treatment of open fractures and joint replacement surgery are increasing, but the direct cost is much higher compared to the conventional wound dressing. However, previous studies have shown that NPWT can reduce postoperative complications such as wound dehiscence and infection. STS surgery that is often combined with pre-or postoperative radiation therapy is a high-risk procedure concerning wound complications and postoperative infections. A retrospective study showed that NPWT reduced the risk of wound complications in patients with lower extremity STS treated with preoperative radiation and the use of NPWT was not associated with an increased risk of local recurrence.
Methods
Study design
RCT (no blinding) where the patients will be randomized to wound closure with staples and either NPWT (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
Randomization
All 160 patients will in the operating room be randomized (randomization with 80 in each group) to receive one of the two treatment:
Group A: Standard wound closure with staples and conventional wound dressing. Group B: Wound closure with staples and NPWT (PREVENA PLUS™ Incision Management System).
Block randomization with 8 patients in each block stratified for upper extremity/truncal wall or lower extremity STS verified using a computerized irreversible application - the Research Electronic Data Capture (REDCap). The randomization sequence will be computer-generated.
Institutions
\- Department of Orthopedic Surgery, Rigshospitalet, University of Copenhagen and Department of Orthopedic Surgery, Aarhus University Hospital: The surgeries will be performed in these two department, both are tertiary multidisciplinary center performing highly specialized tumor surgeries.
Materials
Patients
Identification and inclusion Patients evaluated at a multidisciplinary conference and afterward with a biopsy verified STS will be identified in Sundhedsplatformen (electronic patient journal), the only information needed from the patient journal prior informed consent is when they will meet in the outpatient clinic. Patients eligible for inclusion will at their first outpatient visit to plan further final surgery be informed about the study written and orally. On the day of their surgery written informed consent will be obtained if they want to participate in this study. No patient will have below 48 hours to answer, complied with the Helsinki declaration.
All patients will be informed orally and written by the principal investigator, information will be given in a separate room allocated for only the patient and if wanted the assessor, so interruption occurs. All patient will be asked if they want an assessor and so a new meeting will be allocated and the information will again in a separate room allocated for the patient and the assessor be given by the principal investigator.
The written informed consent gives the principal investigator, sponsor and sponsor's representatives as well as any control authority direct access to obtain information in the patient's medical record, etc., including electronic medical record, in order to see information about the subject's health, which is necessary in carrying out the research project and for control purposes, including self-monitoring, quality control and monitoring, which they are required to perform.
The participants are covered by the Danish Patient Compensation Association.
Research plan
1. Clinical wound follow-up (n=160): preoperatively, 7 days, time for removal of staples and 4 months after surgery. To all examinations, clinical photos of the wound will be taken and stored in Sundhedsplatformen (electronic patient journal).
2. Clinical function evaluation (n=160): Musculoskeletal Tumor Society Score (MSTS) and Toronto Extremity Salvage Score (TESS) 4 months and 1 year postoperatively.
Follow-up
Patient's wounds will be followed with photo documentation on day 0, day 7, at definitive wound healing (removal of staples), 4 months postoperatively and in case of major wound complication by a member of the department staff or research group.
Follow-up from day 7 and further on will be performed in the outpatient regime, at Rigshospitalet, orthopedic department or the ortopedic department at Aarhus University Hospital, patients will be convened through e-boks and if necessary, transport will be provided.
Calculation of sample size
In the study of O'Sullivan et al. a major wound complication within 4 months postoperatively was identified in 16 out of 94 (17%) in the group of STS patients treated with surgery and postoperative radiation therapy. There exist no studies evaluating the effect of NPWT on wound complications after surgery for STS combined with postoperative radiation therapy. However, in retrospective studies it was found that NPWT reduced the risk of wound complications from 47% to 8% (83% reduction) in patients with lower extremity STS treated with preoperative radiation \[14\] and from 27% to 7% (75% reduction) in patients undergoing hip and knee revision surgery.
In a study design with an 80% risk of avoiding type II error, a 5% risk of type I error and an 80% wound complication risk reduction in a population similar to the study by O'Sullivan et al. the investigators will need to include 154 STS patients (77 in each group) in an RCT.
To make allowance for dropouts (since the follow-up period regarding the primary study endpoint is only 4 months = 120 days few dropouts are expected) during the study period the investigators plan to include 160 patients.
Risks, side effects and disadvantages
The investigators do not expect that the patients participating in the study will experience any special side effects or complications related directly to the specific use of NPWT or the standard wound closure. The dressing may for some patients give a mild skin irritation of the skin under the enclosed dressing or a slight discomfort with having to wear an occlusive dressing. Any skin irritation that is transient (i.e., resolves within 24 hours following device use and requires no medical intervention), will not be classified as an adverse device effect. Some blistering formations have been reported in relation to total hip and knee replacement surgery, but no more than tape trauma in patients with conventional dressing.
A retrospective study showed that NPWT reduced the risk of wound complications in patients with lower extremity STS treated with preoperative radiation and the use of NPWT was not associated with an increased risk of local recurrence.
No risk or side effects are reported by the manufacture when adhering to the manual of use.
Prevena™ NPWT are used daily at the orthopedic department, it is a CE classified medical devised and due to use in the recommended field approval from danish medicines agency are not necessary.
Ethical considerations
Approval from the Scientific Ethical Committee (H-21013549) and the Data Protection Agency (P-2021-150) has been obtained and the study is registered at clinicaltrial.gov NCT04960332. All patients will receive both oral and written information before written informed consent to participate is obtained.
The regulation from data protection regulation and data protection act will always be followed and a permission from data protection agency have been obtained (P-2021-150).
The significant use of the present study is new knowledge concerning the best way to treat a certain group of patients with deep-seated STS of an extremity or the trunk wall. Knowledge from our study will benefit society in general, and optimize utilization of resources, in terms of the best treatment for future patients.
In case of serious adverse preliminary results, data will be analyzed and if one of the treatments is found to cause significant critical problems compared to the other (p\<0.05), the study will be ended. The study is thus designed to minimize unnecessary risks to the patients.
Statistical analysis
Fisher's exact test will be used for categorical variables. Depending on if the data could be considered normally distributed or not, a t-test for unpaired data or Mann-Whitney U test will be used for continuous variables.
Kaplan Meier survival analysis for overall survival (with log-rank test for comparison of groups). In case of an assumption of a difference in time to delayed wound healing, competing risk analysis will be used to address differences between the groups with death and amputation as competing factors.
All analyses will be performed in accordance with the intention-to-treat principles.
Two-sided p-values below 0.05 will be considered statistically significant.
Time frame
According to the latest report from the Danish Sarcoma Registry, there were approximately 900 newly diagnosed sarcomas in Eastern Denmark (Rigshospitalet) during the 5 years from 2014 to 2018. The majority, but not all of the patients are suffering from high-malignant deep-seated STS of the extremities or the trunk wall. The inclusion of patients in the study will start at the first half of of 2021 thus leaving at least 3 years for inclusion and reserve 6 months for the PhD-student to do data management and writing.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Sarcoma
Cancer
Neoplasms, Connective and Soft Tissue
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Prospective randomized controlled trial
Primary Study Purpose
TREATMENT
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Standard treatment
Group A: Standard wound closure with staples and conventional wound dressing.
Group Type
NO_INTERVENTION
No interventions assigned to this group
Prevena
Group B: Wound closure with staples and Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System).
Group Type
EXPERIMENTAL
Prevena
Intervention Type
DEVICE
RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Prevena
RCT (no blinding) where the patients will be randomized to wound closure with staples and either Negative Pressure Wound Therapy (PREVENA PLUS™ Incision Management System) for 7 days or a conventional wound dressing.
Intervention Type
DEVICE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
\- Surgery for a deep-seated STS of an extremity or the trunk wall at Rigshospitalet.
Exclusion Criteria
* Age \< 18 years
* Wound closure not possible without plastic surgery (pedicled or free flaps)
* Low malignant (Trojani grade 1) STS or borderline tumors
* Pre- or postoperative chemotherapy
* Preoperative radiotherapy to the local site.
* Allergic or hypersensitive to acrylic adhesives or silver
* Unwilling or unable to provide informed consent
* Inability to comply with planned study procedures
* Patients with metastatic disease.
* Patients with ischemic surgery such as bypass or endovascular prosthesis
* Wound closure not possible without plastic surgery (pedicled or free flaps)
* Low malignant (Trojani grade 1) STS or borderline tumors
* Pre- or postoperative chemotherapy
* Preoperative radiotherapy to the local site.
* Allergic or hypersensitive to acrylic adhesives or silver
* Unwilling or unable to provide informed consent
* Inability to comply with planned study procedures
* Patients with metastatic disease.
* Patients with ischemic surgery such as bypass or endovascular prosthesis
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rigshospitalet, Denmark
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Andrea Thorn
PhD student and Medical Doctor, department of orthopedic surgery
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrea Thorn, MD
Role: PRINCIPAL_INVESTIGATOR
Rigshospitalet, Denmark
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aarhus University Hospital
Aarhus, , Denmark
Site Status
RECRUITING
Rigshospitalet
Copenhagen, , Denmark
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Denmark
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Michael Mørk Petersen, Professor
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Yilmaz M, Thorn A, Sorensen MS, Jensen CL, Petersen MM. Effect of negative pressure wound therapy after surgical removal of deep-seated high-malignant soft tissue sarcomas of the extremities and trunk wall-study protocol for a randomized controlled trial. Trials. 2022 Jun 18;23(1):507. doi: 10.1186/s13063-022-06468-6.
Reference Type
DERIVED
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Prevena-RH-2021
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Negative Pressure Wound Therapy in Traumatic Skin Loss
NCT05653297
UNKNOWN
Negative Pressure Wound Therapy to Reduce Surgical Site Infection
NCT01905397
COMPLETED
NA
Negative Pressure Wound Therapy for Wound Healing After Stoma Reversal
NCT03781206
UNKNOWN
NA
Single-Use Negative Pressure Wound Therapy System vs. Traditional Negative Pressure Wound Therapy System (tNPWT)
NCT02470806
COMPLETED
NA
A Case-Control Study of Negative Pressure Platform Wound Devices (NP-PWD) for Skin and Soft Tissue Defects
NCT06552481
COMPLETED
NA
Evaluation of Negative Pressure Wound Therapy in the Treatment of DFUs Incl. Post Amputation Wounds.
NCT01011387
COMPLETED
NA
Diabetes Related Foot Ulcers with Negative Pressure Wound Therapy
NCT06721754
RECRUITING
NA
The Study of Wound Dressings for Portable NPWT
NCT03135964
COMPLETED
NA
Negative Pressure Incision Management System in Infrainguinal Vascular Surgery
NCT03395613
UNKNOWN
NA
Negative Pressure Wound Therapy. Therapy Effects and the Impact on the Patient's Quality of Life
NCT01191567
TERMINATED
NA
A Comparative Efficacy Study: Treatment for Non-healing Diabetic Foot Ulcers
NCT01858545
TERMINATED
NA
Effect of Negative Pressure Wound Therapy for Soft Tissue Injuries of Foot and Ankle in Patients at a Tertiary Care Hospital
NCT04569305
COMPLETED
NA
Malignant Wounds, Wound Treatment, Psycho-Social Support and Relaxation Therapy
NCT00435474
COMPLETED
PHASE3
Extracorporeal Shockwave Treatment for Chronic Soft Tissue Wounds
NCT00545896
COMPLETED
PHASE2
Negative Pressure Wound Therapy Registry
NCT02467998
UNKNOWN
Negative Pressure Wound Therapy in Diabetic Wounds
NCT05041244
COMPLETED
NA
Adipose Derived Regenerative Cellular Therapy of Chronic Wounds
NCT02092870
COMPLETED
PHASE2
Exploring the Effectiveness of Unpowered Negative Pressure Wound Therapy
NCT06911307
NOT_YET_RECRUITING
NA
Evaluating the Safety and Efficacy of Fractionated Carbon Dioxide Therapy in Postoperative Lower Extremity Wound Healing
NCT03644849
COMPLETED
NA
Study to Evaluate the PICO 14 Negative Pressure Wound Therapy System in the Management of Acute and Chronic Wounds
NCT05234632
TERMINATED
Negative Pressure Wound Therapy in Groin Dissection
NCT02408835
UNKNOWN
NA
Negative Pressure Wound Therapy as a Drug Delivery System
NCT02463487
COMPLETED
NA
Treatment Study of Negative Pressure Wound Therapy for Diabetic Foot Wounds
NCT01480362
COMPLETED
NA